Skip to main navigation Skip to search Skip to main content

A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial

  • Reinier C A van Linschoten
  • , Fenna M Jansen
  • , Renske W M Pauwels
  • , Lisa J T Smits
  • , Femke Atsma
  • , Wietske Kievit
  • , Dirk J de Jong
  • , Annemarie C de Vries
  • , Paul J Boekema
  • , Rachel L West
  • , Alexander G L Bodelier
  • , Ingrid A M Gisbertz
  • , Frank H J Wolfhagen
  • , Tessa E H Römkens
  • , Maurice W M D Lutgens
  • , Adriaan A van Bodegraven
  • , Bas Oldenburg
  • , Marieke J Pierik
  • , Maurice G V M Russel
  • , Nanne K de Boer
    • Rosalie C Mallant-Hent, Pieter C J Ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen*, LADI study group, the Dutch Initiative on Crohn, Colitis (ICC)
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Nursing and Health Professions

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Neuroscience